Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
Esophageal cancer is a common malignant tumor in china, occupies the second place of malignant tumor morbidity and mortality, the overall 5-year survival rate less than 20%.
Advanced Esophageal Squamous Carcinoma
DRUG: Apatinib
Progression-free survival (PFS), The first day of treatment to the date that disease progression is reported., 6 months
Total Survival (OS), the first day of treatment to death or last survival confirm date, up to 24 months
Esophageal cancer is a common malignant tumor in china, occupies the second place of malignant tumor morbidity and mortality, the overall 5-year survival rate less than 20%.